Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Medical Ultrasonics
Erschienen in: Journal of Medical Ultrasonics 4/2020

03.08.2020 | Special Feature: Review Article

Advances in ultrasound elastography for nonalcoholic fatty liver disease

verfasst von: Masato Yoneda, Yasushi Honda, Asako Nogami, Kento Imajo, Atsushi Nakajima

Erschienen in: Journal of Medical Ultrasonics | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

The prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) has increased rapidly worldwide, making NAFLD/NASH an important global health problem from both a medical and socioeconomic standpoint. NAFLD is also regarded as a liver component of metabolic syndrome and is reported to be associated with the risk factors for metabolic syndrome. It has been suggested that NAFLD/NASH be recognized both as a liver-specific disease and as an early mediator of systemic diseases. Liver biopsy is recommended as the gold standard method for the diagnosis of NASH and for the staging of liver fibrosis in patients with NAFLD. However, because of its high cost, high risk, and high weightage as a healthcare resource, invasive liver biopsy is a poorly suited diagnostic test for such a highly prevalent condition. Therefore, the development of reliable noninvasive methods for the assessment of liver fibrosis has been sought to estimate the risk of progression of NASH to cirrhosis, estimate the risk of cardiovascular events, aid in the surveillance for HCC, and guide therapy in patients with NAFLD/NASH. In this review, we highlight the principles and recent advances in ultrasound elastography techniques (Real-time Tissue Elastography®, vibration-controlled transient elastography, point shear wave elastography, and two-dimensional shear wave elastography) used to evaluate the liver fibrosis stage and steatosis grade in patients with NAFLD.
Literatur
1.
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.PubMed
2.
Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389–98.PubMedCrossRef
3.
Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643–654.e1–9.PubMedCrossRef
4.
Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–54.PubMedCrossRef
5.
Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.PubMedCrossRef
6.
7.
Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65.PubMedCrossRef
8.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.PubMedCrossRef
9.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57.PubMedCrossRef
10.
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–402.
11.
Cadranel JF. Good clinical practice guidelines for fine needle aspiration biopsy of the liver: past, present and future. Gastroenterol Clin Biol. 2002;26:823–4.PubMed
12.
Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50:364–77.PubMedCrossRef
13.
14.
Bedossa P, Dargere D, Paradise V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449–57.PubMedCrossRef
15.
Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986;1:523–5.PubMedCrossRef
16.
17.
Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904.PubMedCrossRef
18.
Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705–25.PubMedCrossRef
19.
Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082–90.PubMedCrossRef
20.
Xia MF, Yan HM, He WY, et al. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity (Silver Spring). 2012;20:444–52.CrossRef
21.
Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1209–22.PubMedCrossRef
22.
Paige JS, Bernstein GS, Heba E, et al. A pilot comparative study of quantitative ultrasound, conventional ultrasound, and MRI for predicting histology-determined steatosis grade in adult nonalcoholic fatty liver disease. AJR Am J Roentgenol. 2017;208:W168–77.PubMedPubMedCentralCrossRef
23.
Cengiz M, Sentürk S, Cetin B, et al. Sonographic assessment of fatty liver: intraobserver and interobserver variability. Int J Clin Exp Med. 2014;7:5453–60 (eCollection 2014).PubMedPubMedCentral
24.
Zhang B, Ding F, Chen T, et al. Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content. World J Gastroenterol. 2014;20:17985–92.PubMedPubMedCentralCrossRef
25.
Dietrich C, Bamber J, Berzigotti A, et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Eur J Ultrasound. 2017;38:e16–47.
26.
Friedrich-Rust M, Poynard T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol. 2016;13:402–11.PubMedCrossRef
27.
Ferraioli G, Wong VW, Castera L, et al. Liver ultrasound elastography: an update to the world federation for ultrasound in medicine and biology guidelines and recommendations. Ultrasound Med Biol. 2018;44:2419–40.PubMedCrossRef
28.
Matsumura T, Shiina T, Oosaka T, et al. Development of real- time tissue elastography. MEDIX. 2004;41:30–5.
29.
Shiina T, Nightingale KR, Palmeri ML, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: part 1: basic principles and terminology. Ultrasound Med Biol. 2015;41:1126–47.PubMedCrossRef
30.
Ochi H, Hirooka M, Koizumi Y, et al. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology. 2012;56:1271–8.PubMedCrossRef
31.
Sandrin L, Tanter M, Gennisson JL, et al. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control. 2002;49:436–46.PubMedCrossRef
32.
Yoneda M, Imajo K, Nakajima A. Non-invasive diagnosis of nonalcoholic fatty liver disease. Am J Gastroenterol. 2018;113:1409–11.PubMedCrossRef
33.
34.
Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008;40:371–8.PubMedCrossRef
35.
de Lédinghen V, Vergniol J, Foucher J, et al. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 2010;30:1043–8.PubMedCrossRef
36.
Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254–69.PubMedCrossRef
37.
Jiang W, Huang S, Teng H. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open. 2018;8(8):e021787.PubMedPubMedCentralCrossRef
38.
Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486–501.PubMedCrossRef
39.
Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454–62.PubMedCrossRef
40.
de Lédinghen V, Vergniol J. Transient elastography (FibroScan). Gastroenterol Clin Biol. 2008;32:58–67.PubMedCrossRef
41.
Boursier J, Vergniol J, Guillet A, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol. 2016;65:570–8.PubMedCrossRef
42.
Kamarajah SK, Chan WK, Mustapha NRN, et al. Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease. Hepatol Int. 2018;12:44–5.PubMedCrossRef
43.
Nogami A, Yoneda M, Kobayashi T, et al. Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease. Hepatol Res. 2019;49:872–80.PubMedCrossRef
44.
45.
Mederacke I, Wursthorn K, Kirschner J, et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int. 2009;29:1500–6.PubMedCrossRef
46.
Popescu A, Bota S, Sporea I, et al. The influence of food intake on liver stiffness values assessed by acoustic radiation force impulse elastography-preliminary results. Ultrasound Med Biol. 2013;39:579–84.PubMedCrossRef
47.
Millonig G, Friedrich S, Adolf S, et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol. 2010;52:206–10.PubMedCrossRef
48.
Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology. 2008;48:1718–23.PubMedCrossRef
49.
Loustaud-Ratti VR, Cypierre A, Rousseau A, et al. Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid. 2011;18:19–24.PubMedCrossRef
50.
Wong GL, Kwok R, Wong VW. Huge adrenal hemangioma: a rare cause of deceivingly high liver stiffness measurement by transient elastography. Clin Gastroenterol Hepatol. 2015;13:e37–8.PubMedCrossRef
51.
Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362–73.PubMedPubMedCentralCrossRef
52.
Oeda S, Takahashi H, Imajo K, et al. Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: comparison between M and XL probes. Hepatol Res. 2020;50:831–9.PubMedCrossRef
53.
Yoneda M, Suzuki K, Kato S, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology. 2010;256:640–7.PubMedCrossRef
54.
Cassinotto C, Boursier J, de Lédinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology. 2016;63:1817–27.PubMedCrossRef
55.
Liu H, Fu J, Hong R, et al. Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: a systematic review & meta-analysis. PLoS One. 2015;10(7):e0127782.PubMedPubMedCentralCrossRef
56.
Lin Y, Li H, Jin C, et al. The diagnostic accuracy of liver fibrosis in non-viral liver diseases using acoustic radiation force impulse elastography: a systematic review and meta-analysis. PLoS One. 2020;15:e0227358.PubMedPubMedCentralCrossRef
57.
Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012;19:e212–9.PubMedCrossRef
58.
Frulio N, Trillaud H. Ultrasound elastography in liver. Diagn Interv Imaging. 2013;94:515–34.PubMedCrossRef
59.
Muller M, Gennisson JL, Deffieux T, et al. Quantitative viscoelasticity mapping of human liver using supersonic shear imaging: preliminary in vivo feasibility study. Ultrasound Med Biol. 2009;35:219–29.PubMedCrossRef
60.
Bercoff J, Tanter M, Fink M. Supersonic shear imaging: a new technique for soft tissue elasticity mapping. IEEE Trans Ultrason Ferroelectr Freq Control. 2004;51:396–409.PubMedCrossRef
61.
Herrmann E, de Lédinghen V, Cassinotto C, et al. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis. Hepatology. 2018;67:260–72.PubMedCrossRef
62.
Yoneda M, Thomas E, Sclair SN, et al. Supersonic shear imaging and transient elastography with the XL probe accurately detect fibrosis in overweight or obese patients with chronic liver disease. Clin Gastroenterol Hepatol. 2015;13(1502–9):e5.
63.
Wong GL, Wong VW, Chim AM, et al. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J Gastroenterol Hepatol. 2011;26:300–5.PubMedCrossRef
64.
Furlan A, Tublin ME, Yu L, et al. Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease. AJR Am J Roentgenol. 2020;214(1):W20–6.PubMedCrossRef
65.
Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012;107:1862–71.PubMedCrossRef
66.
Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022–30.PubMedCrossRef
67.
Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(156–163):e2.
68.
Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–82.PubMedCrossRef
69.
Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2014;29:1470–6.PubMedCrossRef
70.
Fujimori N, Tanaka N, Shibata S, et al. Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis. Hepatol Res. 2016;46:1019–27.PubMedCrossRef
71.
Liu K, Wong VW, Lau K, et al. Prognostic value of controlled attenuation parameter by transient elastography. Am J Gastroenterol. 2017;112:1812–23.PubMedCrossRef
72.
Tada T, Iijima H, Kobayashi N, et al. Usefulness of attenuation imaging with an ultrasound scanner for the evaluation of hepatic steatosis. Ultrasound Med Biol. 2019;45:2679–87.PubMedCrossRef
73.
Yoo J, Lee JM, Joo I, et al. Reproducibility of ultrasound attenuation imaging for the noninvasive evaluation of hepatic steatosis. Ultrasonography. 2020;39:121–9.PubMedCrossRef
74.
Tamaki N, Koizumi Y, Hirooka M, et al. Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. Hepatol Res. 2018;48:821–8.PubMedCrossRef
75.
Koizumi Y, Hirooka M, Tamaki N, et al. New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode. PLoS One. 2019;14:e0221548.PubMedPubMedCentralCrossRef
76.
Fujiwara Y, Kuroda H, Abe T, et al. The B-mode image-guided ultrasound attenuation parameter accurately detects hepatic steatosis in chronic liver disease. Ultrasound Med Biol. 2018;44:2223–32.PubMedCrossRef
77.
Tada T, Kumada T, Toyoda H, et al. Utility of attenuation coefficient measurement using an ultrasound-guided attenuation parameter for evaluation of hepatic steatosis: comparison with MRI-determined proton density fat fraction. AJR Am J Roentgenol. 2019;212:332–41.PubMedCrossRef
78.
Tada T, Kumada T, Toyoda H, et al. Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis. Hepatol Res. 2020;50:190–8.PubMedCrossRef
79.
Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology. 2016;64:19–22.PubMedCrossRef
80.
Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(389–97):e10.
81.
Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 2013;144:102–11.PubMedCrossRef
82.
Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140:1970–9.PubMedCrossRef
Metadaten
Titel
Advances in ultrasound elastography for nonalcoholic fatty liver disease
verfasst von
Masato Yoneda
Yasushi Honda
Asako Nogami
Kento Imajo
Atsushi Nakajima
Publikationsdatum
03.08.2020
Verlag
Springer Singapore
Erschienen in
Journal of Medical Ultrasonics / Ausgabe 4/2020
Print ISSN: 1346-4523
Elektronische ISSN: 1613-2254
DOI
https://doi.org/10.1007/s10396-020-01040-8

Weitere Artikel der Ausgabe 4/2020

Journal of Medical Ultrasonics 4/2020 Zur Ausgabe

Original Article–Cardiology

Regional heterogeneity of afterload sensitivity in myocardial strain

Original Article–Orthopedics

Discrimination of well-differentiated liposarcoma from benign lipoma on sonography: an uncontrolled retrospective study

Image–Cardiology

A case of subvalvular pulmonary stenosis differentiated from a double-chambered right ventricle by transesophageal echocardiography: importance of detecting the pulmonary valve

Image–Pediatrics

Flickering sign on superb microvascular imaging in patients with infantile hypertrophic pyloric stenosis

Original Article–Pediatrics

Comparison of sonographic findings between pediatric patients with mediastinitis and without mediastinitis after cardiovascular surgery

Special Feature: Review Article

Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

S3-Leitlinie zu Pankreaskrebs aktualisiert

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

13.04.2024 | Klinik aktuell | Kongressbericht | Nachrichten

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet
weitere anzeigen

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen